Skip to main content
Erschienen in: Current Obesity Reports 2/2015

01.06.2015 | Obesity Treatment (CM Apovian, Section Editor)

Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action

verfasst von: J. Grams, W. Timothy Garvey

Erschienen in: Current Obesity Reports | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Weight loss, whether achieved by lifestyle intervention, pharmacotherapy, or bariatric surgery, is highly effective as a primary interventional strategy in both the prevention and treatment of type 2 diabetes. In high-risk patients with prediabetes and/or metabolic syndrome, weight loss effectively prevents progression to type 2 diabetes mellitus (T2DM) and improves cardiovascular risk factors. These benefits are the result of improvements in insulin resistance, which is central to the pathophysiology of cardiometabolic disease. In patients with T2DM, weight loss improves glycemia, while reducing the need for conventional glucose-lowering medicines, by affecting all three processes that produce and sustain the hyperglycemic state, namely via increments in peripheral insulin sensitivity with improvements in insulin signal transduction at the cellular level, more robust insulin secretory responses, and reduced rates of hepatic glucose production. In both nondiabetic and diabetic subjects, hypocaloric feeding (e.g., treatment with very low-calorie diet or bariatric surgery) produces a rapid improvement in insulin sensitivity due to mobilization of fat from the intramyocellular, intrahepatocellular, and intra-abdominal compartments, and via a more long-term mechanism that correlates with the loss of total body fat. In diabetes, by improving glycemia, weight loss also enhances glucose homeostasis by reversing the defects in insulin action and secretion attributable to glucose toxicity. Regardless of the therapeutic approach, weight loss of ∼10 % maximally prevents future diabetes in patients with prediabetes or metabolic syndrome. In T2DM, greater degrees of weight loss lead to progressive improvements in glucose homeostasis. Therefore, when accompanied by greater weight loss, the metabolic benefits following bariatric surgery are generally more pronounced than those achieved following lifestyle and medical treatment. In addition, the mechanisms by which bariatric operations improve diabetes may include both weight-dependent and weight-independent mechanisms, and the latter may involve changes in gut hormones, bile acids, or gut microflora.
Literatur
1.
Zurück zum Zitat Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011–2012. J Amer Med Assoc. 2014;311:806–14. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011–2012. J Amer Med Assoc. 2014;311:806–14.
2.
Zurück zum Zitat Finkelstein EA, Trogdon JG, Cohen JW, et al. Annual medical spending attributable to obesity: payer-and-service-specific estimates. Health Aff. 2009;28:w822–w31. Finkelstein EA, Trogdon JG, Cohen JW, et al. Annual medical spending attributable to obesity: payer-and-service-specific estimates. Health Aff. 2009;28:w822–w31.
3.
Zurück zum Zitat Garber AJ, Handelsman Y, Einhorn D, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14:933–46.PubMed Garber AJ, Handelsman Y, Einhorn D, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14:933–46.PubMed
4.
Zurück zum Zitat American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38 Suppl 1:S8–S16. American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38 Suppl 1:S8–S16.
5.
Zurück zum Zitat Grundy SM, Brewer Jr HB, Cleeman JI, American Heart A. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–38.PubMed Grundy SM, Brewer Jr HB, Cleeman JI, American Heart A. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–38.PubMed
6.
Zurück zum Zitat Eckel R, Grundy S, Zimmet P. The metabolic syndrome. Lancet. 2005;365:1415–28.PubMed Eckel R, Grundy S, Zimmet P. The metabolic syndrome. Lancet. 2005;365:1415–28.PubMed
7.
Zurück zum Zitat Milicevic Z, Raz J, Beattie SD, et al. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care. 2008;31(2):S155–60.PubMed Milicevic Z, Raz J, Beattie SD, et al. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care. 2008;31(2):S155–60.PubMed
8.
Zurück zum Zitat Van Gaal LF, Mentens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875–80.PubMed Van Gaal LF, Mentens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875–80.PubMed
9.
Zurück zum Zitat Guo F, Moellering DR, Garvey WT. The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity. Obesity. 2014;22:110–18.PubMedCentralPubMed Guo F, Moellering DR, Garvey WT. The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity. Obesity. 2014;22:110–18.PubMedCentralPubMed
10.
Zurück zum Zitat Nigro J, Osman N, Dart AM, et al. Insulin resistance and atherosclerosis. Endocr Rev. 2006;27:242–59.PubMed Nigro J, Osman N, Dart AM, et al. Insulin resistance and atherosclerosis. Endocr Rev. 2006;27:242–59.PubMed
11.
Zurück zum Zitat Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219–46.PubMed Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219–46.PubMed
12.
Zurück zum Zitat Després J-P, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881–7.PubMed Després J-P, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881–7.PubMed
13.
Zurück zum Zitat Ärnlöv J, Ingelsson E, Sundström J, et al. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation. 2010;121:230–6.PubMed Ärnlöv J, Ingelsson E, Sundström J, et al. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation. 2010;121:230–6.PubMed
14.
Zurück zum Zitat Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007;30:753–9.PubMed Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007;30:753–9.PubMed
15.
Zurück zum Zitat Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540–59.PubMed Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540–59.PubMed
16.
Zurück zum Zitat UKPDS Group. UK prospective diabetes study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients. Metabolism. 1990;39:905–12. UKPDS Group. UK prospective diabetes study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients. Metabolism. 1990;39:905–12.
17.
Zurück zum Zitat Bosello O, Armellini F, Zamboni M, et al. The benefits of modest weight loss in type II diabetes. Int J Obes Relat Metab Disord. 1997;21 Suppl 1:S10–3.PubMed Bosello O, Armellini F, Zamboni M, et al. The benefits of modest weight loss in type II diabetes. Int J Obes Relat Metab Disord. 1997;21 Suppl 1:S10–3.PubMed
18.
Zurück zum Zitat Garber AJ, Abrahamson MJ, Barzilay JI, et al. American association of clinical endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement—executive summary. Endocr Pract. 2013;19:536–57.PubMedCentralPubMed Garber AJ, Abrahamson MJ, Barzilay JI, et al. American association of clinical endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement—executive summary. Endocr Pract. 2013;19:536–57.PubMedCentralPubMed
19.
Zurück zum Zitat Norris SL, Zhang X, Avenell A, et al. Long-term non-pharmacological weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev. 2005;CD005270. Norris SL, Zhang X, Avenell A, et al. Long-term non-pharmacological weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev. 2005;CD005270.
20.
Zurück zum Zitat Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532–46.PubMed Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532–46.PubMed
21.
Zurück zum Zitat Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. the Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537–44.PubMed Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. the Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537–44.PubMed
22.
Zurück zum Zitat Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.PubMed Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.PubMed
23.
Zurück zum Zitat Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.PubMed Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.PubMed
24.
Zurück zum Zitat Deedwania PC, Volkova N. Current treatment options for the metabolic syndrome. Curr Treat Options Cardiovasc Med. 2005;7:61–74.PubMed Deedwania PC, Volkova N. Current treatment options for the metabolic syndrome. Curr Treat Options Cardiovasc Med. 2005;7:61–74.PubMed
25.
Zurück zum Zitat Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168:1609–16.PubMed Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168:1609–16.PubMed
26.
Zurück zum Zitat Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med. 2008;168:1617–24.PubMed Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med. 2008;168:1617–24.PubMed
27.
Zurück zum Zitat Meigs JB, Wilson PW, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006;91:2906–12.PubMed Meigs JB, Wilson PW, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006;91:2906–12.PubMed
28.
Zurück zum Zitat Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366:1640–9.PubMed Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366:1640–9.PubMed
29.
Zurück zum Zitat Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29:2102–7.PubMedCentralPubMed Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29:2102–7.PubMedCentralPubMed
30.
Zurück zum Zitat Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–86.PubMedCentral Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–86.PubMedCentral
31.
Zurück zum Zitat Laaksonen DE, Lindstrom J, Lakka TA, et al. Physical activity in the prevention of type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes. 2005;54:158–65.PubMed Laaksonen DE, Lindstrom J, Lakka TA, et al. Physical activity in the prevention of type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes. 2005;54:158–65.PubMed
32.
Zurück zum Zitat Lindström J, Ilanne-Parikka P, Peltonen M, et al. Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673–9.PubMed Lindström J, Ilanne-Parikka P, Peltonen M, et al. Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673–9.PubMed
33.
Zurück zum Zitat Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diab Endocrinol. 2014;2:474–80. Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diab Endocrinol. 2014;2:474–80.
34.
Zurück zum Zitat Barte JC, ter Bogt NC, Bogers RP, et al. Maintenance of weight loss after lifestyle interventions for overweight and obesity, a systematic review. Obes Rev. 2010;11:899–906.PubMed Barte JC, ter Bogt NC, Bogers RP, et al. Maintenance of weight loss after lifestyle interventions for overweight and obesity, a systematic review. Obes Rev. 2010;11:899–906.PubMed
35.
Zurück zum Zitat Wadden TA, Fujioka K, Toubro S, et al. A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet. Obesity. 2010;18:2301–10.PubMed Wadden TA, Fujioka K, Toubro S, et al. A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet. Obesity. 2010;18:2301–10.PubMed
36.
Zurück zum Zitat Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–61.PubMed Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–61.PubMed
37.
Zurück zum Zitat Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297–308.PubMedCentralPubMed Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297–308.PubMedCentralPubMed
38.
Zurück zum Zitat Garvey WT, Ryan DH, Henry R, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care. 2014;37:912–21.PubMedCentralPubMed Garvey WT, Ryan DH, Henry R, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care. 2014;37:912–21.PubMedCentralPubMed
39.
Zurück zum Zitat Wentworth JM, Hensman T, Playfair J, et al. Laparoscopic adjustable gastric banding and progression from impaired fasting glucose to diabetes. Diabetologia. 2014;57:463–8.PubMed Wentworth JM, Hensman T, Playfair J, et al. Laparoscopic adjustable gastric banding and progression from impaired fasting glucose to diabetes. Diabetologia. 2014;57:463–8.PubMed
40.
Zurück zum Zitat Sjöholm K, Anveden A, Peltonen M, et al. Evaluation of current eligibility criteria for bariatric surgery: diabetes prevention and risk factor changes in the Swedish Obese Subjects (SOS) study. Diabetes Care. 2013;36:1335–40.PubMedCentralPubMed Sjöholm K, Anveden A, Peltonen M, et al. Evaluation of current eligibility criteria for bariatric surgery: diabetes prevention and risk factor changes in the Swedish Obese Subjects (SOS) study. Diabetes Care. 2013;36:1335–40.PubMedCentralPubMed
41.
Zurück zum Zitat Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish Obese Subjects. N Engl J Med. 2012;367:695–704.PubMed Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish Obese Subjects. N Engl J Med. 2012;367:695–704.PubMed
42.
Zurück zum Zitat Magliano DJ, Barr EL, Zimmet PZ, et al. Glucose indices, health behaviors, and incidence of diabetes in Australia: the Australian Diabetes, Obesity and Lifestyle study. Diabetes Care. 2008;31:267–72.PubMed Magliano DJ, Barr EL, Zimmet PZ, et al. Glucose indices, health behaviors, and incidence of diabetes in Australia: the Australian Diabetes, Obesity and Lifestyle study. Diabetes Care. 2008;31:267–72.PubMed
43.
Zurück zum Zitat Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. J Amer Med Assoc. 2012;307:56–65. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. J Amer Med Assoc. 2012;307:56–65.
44.••
Zurück zum Zitat Booth H, Khan O, Prevost T, et al. Incidence of type 2 diabetes after bariatric surgery: population-based matched cohort study. Lancet Diab Endocrinol. 2014;2:963–8. This study demonstrates that bariatric surgery is associated with a reduced incidence of T2DM in patients with obesity. Booth H, Khan O, Prevost T, et al. Incidence of type 2 diabetes after bariatric surgery: population-based matched cohort study. Lancet Diab Endocrinol. 2014;2:963–8. This study demonstrates that bariatric surgery is associated with a reduced incidence of T2DM in patients with obesity.
45.
Zurück zum Zitat Guare JC, Wing RR, Grant A. Comparison of obese NIDDM and nondiabetic women: short- and long-term weight loss. Obes Res. 1995;3:329–35.PubMed Guare JC, Wing RR, Grant A. Comparison of obese NIDDM and nondiabetic women: short- and long-term weight loss. Obes Res. 1995;3:329–35.PubMed
46.
Zurück zum Zitat Wing RR, Marcus MD, Epstein LH, et al. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care. 1987;10:563–6.PubMed Wing RR, Marcus MD, Epstein LH, et al. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care. 1987;10:563–6.PubMed
47.
Zurück zum Zitat Henry RR, Chilton R, Garvey WT. New options for the treatment of obesity and type 2 diabetes mellitus (narrative review). J Diab Complic. 2013;27:508–18. Henry RR, Chilton R, Garvey WT. New options for the treatment of obesity and type 2 diabetes mellitus (narrative review). J Diab Complic. 2013;27:508–18.
48.
Zurück zum Zitat Wing RR, Lang W, Wadden TA, The Look AHEAD Research Group, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34:1481–6.PubMedCentralPubMed Wing RR, Lang W, Wadden TA, The Look AHEAD Research Group, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34:1481–6.PubMedCentralPubMed
49.
Zurück zum Zitat Group TLAR, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170:1566–75. Group TLAR, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170:1566–75.
50.
Zurück zum Zitat Belalcazar LM, Haffner SM, Lang W, et al. Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study. Obesity. 2013;21:944–50.PubMedCentralPubMed Belalcazar LM, Haffner SM, Lang W, et al. Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study. Obesity. 2013;21:944–50.PubMedCentralPubMed
51.
Zurück zum Zitat Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–54. Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–54.
52.
Zurück zum Zitat Gregg EW, Chen H, Wagenknecht LE, Look AHEAD Research Group, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. J Amer Med Assoc. 2012;308:2489–96. Gregg EW, Chen H, Wagenknecht LE, Look AHEAD Research Group, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. J Amer Med Assoc. 2012;308:2489–96.
53.
Zurück zum Zitat Foster GD, Borradaile KE, Sanders MH, for the Sleep AHEAD Research Group of the Look AHEAD Research Group, et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med. 2009;169:1916–26.PubMed Foster GD, Borradaile KE, Sanders MH, for the Sleep AHEAD Research Group of the Look AHEAD Research Group, et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med. 2009;169:1916–26.PubMed
54.
Zurück zum Zitat Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998;21:1288–94.PubMed Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998;21:1288–94.PubMed
55.
Zurück zum Zitat Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2002;25:1033–41.PubMed Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2002;25:1033–41.PubMed
56.
Zurück zum Zitat Garvey WT, Ryan DH, Bohannon NJ, et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended-release. Diabetes Care. 2014;37:3309–16.PubMed Garvey WT, Ryan DH, Bohannon NJ, et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended-release. Diabetes Care. 2014;37:3309–16.PubMed
57.
Zurück zum Zitat Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–52.PubMed Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–52.PubMed
58.
Zurück zum Zitat O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426–36.PubMed O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426–36.PubMed
59.
Zurück zum Zitat Hollander P, Gupta AK, Plodkowski R, COR-Diabetes Study Group, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022–9.PubMedCentralPubMed Hollander P, Gupta AK, Plodkowski R, COR-Diabetes Study Group, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022–9.PubMedCentralPubMed
60.
Zurück zum Zitat Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. J Amer Med Assoc. 2014;311:2297–304. Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. J Amer Med Assoc. 2014;311:2297–304.
61.••
Zurück zum Zitat Schauer PR, Bhatt DL, Kirwan JP, STAMPEDE Investigators, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370:2002–13. This study reports 3-year outcomes of the STAMPEDE trial comparing bariatric surgery with medical therapy alone. It demonstrates improved outcomes in glycemic control, body weight, use of glucose-lowering medications, and quality of life in the surgery group.PubMed Schauer PR, Bhatt DL, Kirwan JP, STAMPEDE Investigators, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370:2002–13. This study reports 3-year outcomes of the STAMPEDE trial comparing bariatric surgery with medical therapy alone. It demonstrates improved outcomes in glycemic control, body weight, use of glucose-lowering medications, and quality of life in the surgery group.PubMed
62.
Zurück zum Zitat O’Brien PE, Macdonald L, Anderson M, et al. Long-term outcomes after bariatric surgery: fifteen-year follow-up of adjustable gastric banding and a systematic review of the bariatric surgical literature. Ann Surg. 2013;257:87–94.PubMed O’Brien PE, Macdonald L, Anderson M, et al. Long-term outcomes after bariatric surgery: fifteen-year follow-up of adjustable gastric banding and a systematic review of the bariatric surgical literature. Ann Surg. 2013;257:87–94.PubMed
63.
Zurück zum Zitat Adams TD, Davidson LE, Litwin SE, et al. Gastrointestinal surgery: cardiovascular risk reduction and improved long-term survival in patients with obesity and diabetes. Curr Atheroscler Rep. 2012;14:606–15.PubMed Adams TD, Davidson LE, Litwin SE, et al. Gastrointestinal surgery: cardiovascular risk reduction and improved long-term survival in patients with obesity and diabetes. Curr Atheroscler Rep. 2012;14:606–15.PubMed
64.
Zurück zum Zitat Garvey WT. New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approach. Endocr Pract. 2013;19:864–74.PubMedCentralPubMed Garvey WT. New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approach. Endocr Pract. 2013;19:864–74.PubMedCentralPubMed
65.
Zurück zum Zitat Garvey WT, Garber AJ, Mechanick JI, et al, On Behalf Of The AACE Obesity Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology consensus conference on obesity: building an evidence base for comprehensive action. Endocrine Practice. 2014;20:956--76. Garvey WT, Garber AJ, Mechanick JI, et al, On Behalf Of The AACE Obesity Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology consensus conference on obesity: building an evidence base for comprehensive action. Endocrine Practice. 2014;20:956--76.
66.
Zurück zum Zitat Garvey WT, Garber AJ, Mechanick JI, et al, On Behalf Of The AACE Obesity Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocrine Practice. 2014; 20:977--89. Garvey WT, Garber AJ, Mechanick JI, et al, On Behalf Of The AACE Obesity Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocrine Practice. 2014; 20:977--89.
67.
Zurück zum Zitat Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342--62. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342--62.
68.
Zurück zum Zitat Mechanick JI, Youdim A, Jones DB, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient-2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery. Endocrine Practice. 2013;19:337--72. Mechanick JI, Youdim A, Jones DB, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient-2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery. Endocrine Practice. 2013;19:337--72.
69.
Zurück zum Zitat Heneghan HM, Nissen S, Schauer PR. Gastrointestinal surgery for obesity and diabetes: weight loss and control of hyperglycemia. Curr Atheroscler Rep. 2012;14:579–87.PubMed Heneghan HM, Nissen S, Schauer PR. Gastrointestinal surgery for obesity and diabetes: weight loss and control of hyperglycemia. Curr Atheroscler Rep. 2012;14:579–87.PubMed
70.
Zurück zum Zitat Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. J Amer Med Assoc. 2004;292:1724–37. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. J Amer Med Assoc. 2004;292:1724–37.
71.
Zurück zum Zitat Mingrone G, Panunzi S, Gaetano AD, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577–85.PubMed Mingrone G, Panunzi S, Gaetano AD, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577–85.PubMed
72.
Zurück zum Zitat Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery vs intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567–76.PubMedCentralPubMed Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery vs intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567–76.PubMedCentralPubMed
73.
Zurück zum Zitat Ikramuddin S, Korner J, Lee W-J, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the diabetes surgery study randomized clinical trial. J Amer Med Assoc. 2013;309:2240–9. Ikramuddin S, Korner J, Lee W-J, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the diabetes surgery study randomized clinical trial. J Amer Med Assoc. 2013;309:2240–9.
74.
Zurück zum Zitat Liang Z, Wu Q, Chen B, et al. Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trial. Diabetes Res Clin Pract. 2013;1:50–6. Liang Z, Wu Q, Chen B, et al. Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trial. Diabetes Res Clin Pract. 2013;1:50–6.
75.
Zurück zum Zitat Courcoulas AP, Goodpaster BH, Eagleton JK, et al. Surgical vs medical treatments for type 2 diabetes mellitus: a randomized clinical trial. JAMA Surg. 2014;149:707–15.PubMed Courcoulas AP, Goodpaster BH, Eagleton JK, et al. Surgical vs medical treatments for type 2 diabetes mellitus: a randomized clinical trial. JAMA Surg. 2014;149:707–15.PubMed
76.
Zurück zum Zitat Halperin F, Ding S-A, Simonson DC, et al. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. JAMA Surg. 2014;149:716–26.PubMed Halperin F, Ding S-A, Simonson DC, et al. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. JAMA Surg. 2014;149:716–26.PubMed
77.
Zurück zum Zitat Gill RS, Birch DW, Shi X, et al. Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review. Surg Obes Relat Dis. 2010;6:707-13. Gill RS, Birch DW, Shi X, et al. Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review. Surg Obes Relat Dis. 2010;6:707-13.
78.
Zurück zum Zitat Garvey WT, Lara-Castro C. Diet, Insulin Resistance, and Obesity: Zoning in on Data for Atkins Dieters Living in South Beach. J Clin Endocrinol Metab. 2004;89:4197-205. Garvey WT, Lara-Castro C. Diet, Insulin Resistance, and Obesity: Zoning in on Data for Atkins Dieters Living in South Beach. J Clin Endocrinol Metab. 2004;89:4197-205.
79.
Zurück zum Zitat Weiss R, Taksali SE, Dufour S, et al. The "obese insulin-sensitive" adolescent: importance of adiponectin and lipid partitioning. J Clin Endocrinol Metab. 2005;90:3731-7. Weiss R, Taksali SE, Dufour S, et al. The "obese insulin-sensitive" adolescent: importance of adiponectin and lipid partitioning. J Clin Endocrinol Metab. 2005;90:3731-7.
80.
Zurück zum Zitat Lara-Castro C, Newcomer BR, Rowell J, et al. Effects of short-term very low calorie diet on intramyocellular lipid and insulin sensitivity in nondiabetic and type 2 diabetic subjects. Metabolism. 2008;57:1–8.PubMedCentralPubMed Lara-Castro C, Newcomer BR, Rowell J, et al. Effects of short-term very low calorie diet on intramyocellular lipid and insulin sensitivity in nondiabetic and type 2 diabetic subjects. Metabolism. 2008;57:1–8.PubMedCentralPubMed
81.
Zurück zum Zitat Vitola E, Deivanayagam S, Stein RI, et al. Weight loss reduces liver fat and improves hepatic and skeletal muscle insulin sensitivity in obese adolescents. Obesity. 2009;17:1744–8.PubMedCentralPubMed Vitola E, Deivanayagam S, Stein RI, et al. Weight loss reduces liver fat and improves hepatic and skeletal muscle insulin sensitivity in obese adolescents. Obesity. 2009;17:1744–8.PubMedCentralPubMed
82.
Zurück zum Zitat Henry RR, Wallace P, Olefsky JM. Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. Diabetes. 1986;35:990–8.PubMed Henry RR, Wallace P, Olefsky JM. Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. Diabetes. 1986;35:990–8.PubMed
83.
Zurück zum Zitat Garvey WT, Olefsky JM, Griffin J, et al. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985;34:222–34.PubMed Garvey WT, Olefsky JM, Griffin J, et al. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985;34:222–34.PubMed
84.
Zurück zum Zitat Garvey W, Birnbaum M. Insulin resistance and disease. Bailliere’s clinical endocrinology and metabolism, edited by Ferrannini E: Bailliere Tindall:785–873, 1994. Garvey W, Birnbaum M. Insulin resistance and disease. Bailliere’s clinical endocrinology and metabolism, edited by Ferrannini E: Bailliere Tindall:785–873, 1994.
85.
Zurück zum Zitat Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990;13:610–30.PubMed Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990;13:610–30.PubMed
86.
Zurück zum Zitat Richter EA, Hansen BF, Hansen SA. Glucose-induced insulin resistance of skeletal-muscle glucose transport and uptake. Biochem J. 1988;252:733–7.PubMedCentralPubMed Richter EA, Hansen BF, Hansen SA. Glucose-induced insulin resistance of skeletal-muscle glucose transport and uptake. Biochem J. 1988;252:733–7.PubMedCentralPubMed
87.
Zurück zum Zitat Baron AD, Zhu JS, Zhu JH, et al. Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle. Implications for glucose toxicity. J Clin Invest. 1995;96:2792–801.PubMedCentralPubMed Baron AD, Zhu JS, Zhu JH, et al. Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle. Implications for glucose toxicity. J Clin Invest. 1995;96:2792–801.PubMedCentralPubMed
88.
Zurück zum Zitat Garvey WT, Olefsky JM, Matthaei S, et al. Glucose and insulin co-regulate the glucose transport system in primary cultured adipocytes. A new mechanism of insulin resistance. J Biol Chem. 1987;262:189–97.PubMed Garvey WT, Olefsky JM, Matthaei S, et al. Glucose and insulin co-regulate the glucose transport system in primary cultured adipocytes. A new mechanism of insulin resistance. J Biol Chem. 1987;262:189–97.PubMed
89.
Zurück zum Zitat Bailey CJ, Turner SL. Glucosamine-induced insulin resistance in L6 muscle cells. Diabetes Obes Metab. 2004;6:293–8.PubMed Bailey CJ, Turner SL. Glucosamine-induced insulin resistance in L6 muscle cells. Diabetes Obes Metab. 2004;6:293–8.PubMed
90.
Zurück zum Zitat Marshall S. Role of insulin, adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: a nutritional perspective of diabetes, obesity, and cancer. Sci STKE. 2006;2006:re7.PubMed Marshall S. Role of insulin, adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: a nutritional perspective of diabetes, obesity, and cancer. Sci STKE. 2006;2006:re7.PubMed
91.
Zurück zum Zitat Scarlett JA, Kolterman OG, Ciaraldi TP, et al. Insulin treatment reverses the postreceptor defect in adipocyte 3-O-methylglucose transport in type II diabetes mellitus. J Clin Endocrinol Metab. 1983;56:1195–201.PubMed Scarlett JA, Kolterman OG, Ciaraldi TP, et al. Insulin treatment reverses the postreceptor defect in adipocyte 3-O-methylglucose transport in type II diabetes mellitus. J Clin Endocrinol Metab. 1983;56:1195–201.PubMed
92.
Zurück zum Zitat Friedman JE, Dohm GL, Leggett-Frazier N, et al. Restoration of insulin responsiveness in skeletal muscle of morbidly obese patients after weight loss. Effect on muscle glucose transport and glucose transporter GLUT4. J Clin Invest. 1992;89:701–5.PubMedCentralPubMed Friedman JE, Dohm GL, Leggett-Frazier N, et al. Restoration of insulin responsiveness in skeletal muscle of morbidly obese patients after weight loss. Effect on muscle glucose transport and glucose transporter GLUT4. J Clin Invest. 1992;89:701–5.PubMedCentralPubMed
93.
Zurück zum Zitat Greenfield MS, Doberne L, Rosenthal M, et al. Effect of sulfonylurea treatment on in vivo insulin secretion and action in patients with non-insulin-dependent diabetes mellitus. Diabetes. 1982;31:307–12.PubMed Greenfield MS, Doberne L, Rosenthal M, et al. Effect of sulfonylurea treatment on in vivo insulin secretion and action in patients with non-insulin-dependent diabetes mellitus. Diabetes. 1982;31:307–12.PubMed
94.
Zurück zum Zitat Yki-Jarvinen H, Helve E, Koivisto VA. Hyperglycemia decreases glucose uptake in type I diabetes. Diabetes. 1987;36:892–6.PubMed Yki-Jarvinen H, Helve E, Koivisto VA. Hyperglycemia decreases glucose uptake in type I diabetes. Diabetes. 1987;36:892–6.PubMed
95.
Zurück zum Zitat Bradley D, Magkos F, Klein S. Effects of bariatric surgery on glucose homeostasis and type 2 diabetes. Gastroenterology. 2012;143:897–912.PubMedCentralPubMed Bradley D, Magkos F, Klein S. Effects of bariatric surgery on glucose homeostasis and type 2 diabetes. Gastroenterology. 2012;143:897–912.PubMedCentralPubMed
96.
Zurück zum Zitat Isbell JM, Tamboli RA, Hansen EN, et al. The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en Y gastric bypass surgery. Diabetes Care. 2010;33:1438–42.PubMedCentralPubMed Isbell JM, Tamboli RA, Hansen EN, et al. The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en Y gastric bypass surgery. Diabetes Care. 2010;33:1438–42.PubMedCentralPubMed
97.
Zurück zum Zitat Kadera BE, Lum K, Grant J, et al. Remission of type 2 diabetes after Roux-en Y gastric bypass is associated with greater weight loss. Surg Obes Relat Dis. 2009;5:305–9.PubMed Kadera BE, Lum K, Grant J, et al. Remission of type 2 diabetes after Roux-en Y gastric bypass is associated with greater weight loss. Surg Obes Relat Dis. 2009;5:305–9.PubMed
98.
Zurück zum Zitat Dixon JB. Obesity and diabetes: the impact of bariatric surgery on type-2 diabetes. World J Surg. 2009;33:2014–21.PubMed Dixon JB. Obesity and diabetes: the impact of bariatric surgery on type-2 diabetes. World J Surg. 2009;33:2014–21.PubMed
99.
Zurück zum Zitat Hamza N, Abbas MH, Darwish A, et al. Predictors of remission of type 2 diabetes mellitus after laparoscopic gastric banding and bypass. Surg Obes Relat Dis. 2011;7:691–6.PubMed Hamza N, Abbas MH, Darwish A, et al. Predictors of remission of type 2 diabetes mellitus after laparoscopic gastric banding and bypass. Surg Obes Relat Dis. 2011;7:691–6.PubMed
100.
Zurück zum Zitat Chikunguwo SM, Wolfe LG, Dodson P, et al. Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2010;6:254–9.PubMed Chikunguwo SM, Wolfe LG, Dodson P, et al. Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2010;6:254–9.PubMed
101.
Zurück zum Zitat D’Alessio DA, Prigeon RL, Ensinck JW. Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide I. Diabetes. 1995;44:1433–7.PubMed D’Alessio DA, Prigeon RL, Ensinck JW. Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide I. Diabetes. 1995;44:1433–7.PubMed
102.
Zurück zum Zitat Gutzwiller JP, Drewe J, Göke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999;276:R1541–4.PubMed Gutzwiller JP, Drewe J, Göke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999;276:R1541–4.PubMed
103.
Zurück zum Zitat Flint A, Raben A, Ersbøll AK, et al. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes. 2001;25:781–92. Flint A, Raben A, Ersbøll AK, et al. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes. 2001;25:781–92.
104.
Zurück zum Zitat le Roux CW, Aylwin SJB, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243:108–14.PubMedCentralPubMed le Roux CW, Aylwin SJB, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243:108–14.PubMedCentralPubMed
105.
Zurück zum Zitat Morínigo R, Moizé V, Musri M, et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2006;91:1735–40.PubMed Morínigo R, Moizé V, Musri M, et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2006;91:1735–40.PubMed
106.
Zurück zum Zitat Laferrère B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007;30:1709–16.PubMedCentralPubMed Laferrère B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007;30:1709–16.PubMedCentralPubMed
107.
Zurück zum Zitat Laferrère B. Diabetes remission after bariatric surgery: is it just the incretins. Int J Obes. 2011;35:S22–5. Laferrère B. Diabetes remission after bariatric surgery: is it just the incretins. Int J Obes. 2011;35:S22–5.
108.
Zurück zum Zitat Jørgensen NB, Dirksen C, Bøjsen-Moller KN, et al. Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes. 2013;62:3044–52.PubMedCentralPubMed Jørgensen NB, Dirksen C, Bøjsen-Moller KN, et al. Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes. 2013;62:3044–52.PubMedCentralPubMed
109.
Zurück zum Zitat Salehi M, Prigeon RL, D’Alessio DA. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes. 2011;60:2208–14. Salehi M, Prigeon RL, D’Alessio DA. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes. 2011;60:2208–14.
110.
Zurück zum Zitat Gill RS, Birch DW, Shi X, et al. Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review. Surg Obes Relat Dis. 2010;6:707–13.PubMed Gill RS, Birch DW, Shi X, et al. Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review. Surg Obes Relat Dis. 2010;6:707–13.PubMed
111.
Zurück zum Zitat Nannipieri M, Baldi S, Mari A, et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab. 2013;98:4391–9.PubMed Nannipieri M, Baldi S, Mari A, et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab. 2013;98:4391–9.PubMed
112.
Zurück zum Zitat Korner J, Bessler M, Inabnet W, et al. Exaggerated GLP-1 and blunted GIP secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis. 2007;3:597–301.PubMedCentralPubMed Korner J, Bessler M, Inabnet W, et al. Exaggerated GLP-1 and blunted GIP secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis. 2007;3:597–301.PubMedCentralPubMed
113.
Zurück zum Zitat Laferrère B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:2479–85.PubMedCentralPubMed Laferrère B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:2479–85.PubMedCentralPubMed
114.
Zurück zum Zitat Bojsen-Møller KN, Dirksen C, Jørgensen NB, et al. Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes. 2014;63:1725–37.PubMed Bojsen-Møller KN, Dirksen C, Jørgensen NB, et al. Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes. 2014;63:1725–37.PubMed
115.•
Zurück zum Zitat Knop FK, Taylor R. Mechanism of metabolic advantages after bariatric surgery. Diabetes Care. 2013;36:S287–91. This is a recent review of the mechanisms of bariatric surgery focusing on gastrointestinal factors versus food restriction. PubMedCentralPubMed Knop FK, Taylor R. Mechanism of metabolic advantages after bariatric surgery. Diabetes Care. 2013;36:S287–91. This is a recent review of the mechanisms of bariatric surgery focusing on gastrointestinal factors versus food restriction. PubMedCentralPubMed
116.
Zurück zum Zitat Elahi D, Galiatsatos P, Rabiee A, et al. Mechanisms of type 2 diabetes resolution after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2014;10:1028–40.PubMed Elahi D, Galiatsatos P, Rabiee A, et al. Mechanisms of type 2 diabetes resolution after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2014;10:1028–40.PubMed
117.
Zurück zum Zitat Lingvay I, Guth E, Islam A, et al. Rapid improvement in diabetes after gastric bypass surgery: is it the diet or surgery? Diabetes Care. 2013;36:2741–7.PubMedCentralPubMed Lingvay I, Guth E, Islam A, et al. Rapid improvement in diabetes after gastric bypass surgery: is it the diet or surgery? Diabetes Care. 2013;36:2741–7.PubMedCentralPubMed
118.
Zurück zum Zitat Dirksen C, Hansen DL, Madsbad S, et al. Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion. Diabetes Care. 2010;33:375–7.PubMedCentralPubMed Dirksen C, Hansen DL, Madsbad S, et al. Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion. Diabetes Care. 2010;33:375–7.PubMedCentralPubMed
119.
120.
Zurück zum Zitat Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89:147–91.PubMed Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89:147–91.PubMed
121.
Zurück zum Zitat Glicksman C, Pournaras DJ, Wright M, et al. Postprandial plasma bile acid responses in normal weight and obese subjects. Ann Clin Biochem. 2010;47:482–4.PubMed Glicksman C, Pournaras DJ, Wright M, et al. Postprandial plasma bile acid responses in normal weight and obese subjects. Ann Clin Biochem. 2010;47:482–4.PubMed
122.
Zurück zum Zitat Prawitt J, Caron S, Staels B. Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep. 2011;11:160–6.PubMedCentralPubMed Prawitt J, Caron S, Staels B. Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep. 2011;11:160–6.PubMedCentralPubMed
123.
Zurück zum Zitat Patti M-E, Houten SM, Bianco AC, et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity. 2009;17:1671–7.PubMed Patti M-E, Houten SM, Bianco AC, et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity. 2009;17:1671–7.PubMed
124.
Zurück zum Zitat Nakatani H, Kasama K, Oshiro T, et al. Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. Metabolism. 2009;58:1400–7.PubMed Nakatani H, Kasama K, Oshiro T, et al. Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. Metabolism. 2009;58:1400–7.PubMed
125.
Zurück zum Zitat Jansen PLM, van Werven J, Aarts E, et al. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Dig Dis. 2011;29:48–51.PubMed Jansen PLM, van Werven J, Aarts E, et al. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Dig Dis. 2011;29:48–51.PubMed
126.
Zurück zum Zitat Pournaras DJ, Glicksman C, Vincent RP, et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology. 2012;153:3613–9.PubMedCentralPubMed Pournaras DJ, Glicksman C, Vincent RP, et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology. 2012;153:3613–9.PubMedCentralPubMed
127.
Zurück zum Zitat Ahmad NN, Pfalzer A, Kaplan LM. Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity. Int J Obes. 2013;37:1553–9. Ahmad NN, Pfalzer A, Kaplan LM. Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity. Int J Obes. 2013;37:1553–9.
128.
Zurück zum Zitat Gerhard GS, Styer AM, Wood GC, et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care. 2013;36:1859–64.PubMedCentralPubMed Gerhard GS, Styer AM, Wood GC, et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care. 2013;36:1859–64.PubMedCentralPubMed
129.
Zurück zum Zitat Kohli R, Bradley D, Setchell KD, et al. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab. 2013;98:E708–12.PubMedCentralPubMed Kohli R, Bradley D, Setchell KD, et al. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab. 2013;98:E708–12.PubMedCentralPubMed
130.
Zurück zum Zitat Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89:147–91.PubMed Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89:147–91.PubMed
131.
Zurück zum Zitat Knop FK. Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes? Am J Physiol Endocrinol Metab. 2010;299:E10–3.PubMed Knop FK. Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes? Am J Physiol Endocrinol Metab. 2010;299:E10–3.PubMed
132.
Zurück zum Zitat Kohli R, Kirby M, Setchell KDR, et al. Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity-related comorbidities. Am J Physiol Gastrointest Liver Physiol. 2010;299:G652–60.PubMedCentralPubMed Kohli R, Kirby M, Setchell KDR, et al. Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity-related comorbidities. Am J Physiol Gastrointest Liver Physiol. 2010;299:G652–60.PubMedCentralPubMed
133.
Zurück zum Zitat Kohli R, Setchell KDR, Kirby M, et al. A surgical model in male obese rats uncovers protective effects of bile acids post-bariatric surgery. Endocrinology. 2013;154:2341–51.PubMedCentralPubMed Kohli R, Setchell KDR, Kirby M, et al. A surgical model in male obese rats uncovers protective effects of bile acids post-bariatric surgery. Endocrinology. 2013;154:2341–51.PubMedCentralPubMed
134.•
Zurück zum Zitat Ryan KK, Trmaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014;509:183–8. This study reports that sleeve gastrectomy is associated with increased circulating bile acids and may act through FXR to improve glucose tolerance in a rodent model. Ryan KK, Trmaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014;509:183–8. This study reports that sleeve gastrectomy is associated with increased circulating bile acids and may act through FXR to improve glucose tolerance in a rodent model.
136.
Zurück zum Zitat Ley RE, Turnbaugh PJ, Klein S, et al. Human gut microbes associated with obesity. Nature. 2006;444:1022–3.PubMed Ley RE, Turnbaugh PJ, Klein S, et al. Human gut microbes associated with obesity. Nature. 2006;444:1022–3.PubMed
137.
Zurück zum Zitat Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027–31.PubMed Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027–31.PubMed
138.
Zurück zum Zitat Cani PD, Delzenne NM. Gut microflora as a target for energy and metabolic homeostasis. Curr Opin Clin Nutr Metab Care. 2007;10:729–34.PubMed Cani PD, Delzenne NM. Gut microflora as a target for energy and metabolic homeostasis. Curr Opin Clin Nutr Metab Care. 2007;10:729–34.PubMed
139.
Zurück zum Zitat Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457:480–4.PubMedCentralPubMed Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457:480–4.PubMedCentralPubMed
140.
Zurück zum Zitat Diamant M, Blaak EE, de Vos WM. Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? Obes Rev. 2010;12:272–81.PubMed Diamant M, Blaak EE, de Vos WM. Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? Obes Rev. 2010;12:272–81.PubMed
141.
Zurück zum Zitat Larsen N, Vogensen FK, van den Berg FWJ, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. Plos One. 2010;5:e9085.PubMedCentralPubMed Larsen N, Vogensen FK, van den Berg FWJ, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. Plos One. 2010;5:e9085.PubMedCentralPubMed
142.
Zurück zum Zitat Asrafian H, Beuter M, Ahmed K, et al. Metabolic surgery: an evolution through bariatric animal models. Obes Rev. 2010;11:907–20. Asrafian H, Beuter M, Ahmed K, et al. Metabolic surgery: an evolution through bariatric animal models. Obes Rev. 2010;11:907–20.
143.
Zurück zum Zitat Furet J-P, Kong L-C, Tap J, et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes. 2010;59:3049–57.PubMedCentralPubMed Furet J-P, Kong L-C, Tap J, et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes. 2010;59:3049–57.PubMedCentralPubMed
144.
Zurück zum Zitat le Roux CW, Bueter M, Theis N, et al. Gastric bypass reduces fat intake and preference. Am J Physiol Regul Integr Comp Physiol. 2011;301:R1057–66.PubMedCentralPubMed le Roux CW, Bueter M, Theis N, et al. Gastric bypass reduces fat intake and preference. Am J Physiol Regul Integr Comp Physiol. 2011;301:R1057–66.PubMedCentralPubMed
145.
Zurück zum Zitat Aron-Wisnewsky J, Doré J, Clement K. The importance of the gut microbiota after bariatric surgery. Nat Rev Gastroenterol Hepatol. 2012;9:590–8.PubMed Aron-Wisnewsky J, Doré J, Clement K. The importance of the gut microbiota after bariatric surgery. Nat Rev Gastroenterol Hepatol. 2012;9:590–8.PubMed
146.
Zurück zum Zitat Seto CT, Jeraldo P, Orenstein R, et al. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome. 2014;2:42.PubMedCentralPubMed Seto CT, Jeraldo P, Orenstein R, et al. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome. 2014;2:42.PubMedCentralPubMed
147.
Zurück zum Zitat Zhang H, DiBaise JK, Zuccolo A, et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A. 2009;106:2365–70.PubMedCentralPubMed Zhang H, DiBaise JK, Zuccolo A, et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A. 2009;106:2365–70.PubMedCentralPubMed
148.
Zurück zum Zitat Graessler J, Qin Y, Zhong H, et al. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharmacogenom J. 2013;13:514–22. Graessler J, Qin Y, Zhong H, et al. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharmacogenom J. 2013;13:514–22.
149.
Zurück zum Zitat Kong L-C, Tap J, Aron-Wisnewsky J, et al. Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. Am J Clin Nutr. 2013;98:16–24.PubMed Kong L-C, Tap J, Aron-Wisnewsky J, et al. Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. Am J Clin Nutr. 2013;98:16–24.PubMed
150.
Zurück zum Zitat Everard A, Belzer C, Geurts L, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013;110:9066–71.PubMedCentralPubMed Everard A, Belzer C, Geurts L, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013;110:9066–71.PubMedCentralPubMed
151.
Zurück zum Zitat Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101:15718–23.PubMedCentralPubMed Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101:15718–23.PubMedCentralPubMed
152.
Zurück zum Zitat Brun Paola, Castagliuolo I, Di Leo V, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2006;292:G518–25. Brun Paola, Castagliuolo I, Di Leo V, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2006;292:G518–25.
153.
Zurück zum Zitat Gill SR, Pop M, DeBoy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006;312:1355–9.PubMedCentralPubMed Gill SR, Pop M, DeBoy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006;312:1355–9.PubMedCentralPubMed
154.
Zurück zum Zitat Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–72.PubMed Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–72.PubMed
155.
Zurück zum Zitat Creely SJ, McTernan PG, Kusminski CM, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292:E740–7.PubMed Creely SJ, McTernan PG, Kusminski CM, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292:E740–7.PubMed
156.
Zurück zum Zitat Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57:1470–81.PubMed Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57:1470–81.PubMed
157.
Zurück zum Zitat Schwiertz A, Taras D, Schäfer K, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity. 2010;18:190–5.PubMed Schwiertz A, Taras D, Schäfer K, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity. 2010;18:190–5.PubMed
158.
Zurück zum Zitat Li JV, Ashrafian H, Bueter M, et al. Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut. 2011;60:1214–23.PubMedCentralPubMed Li JV, Ashrafian H, Bueter M, et al. Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut. 2011;60:1214–23.PubMedCentralPubMed
159.•
Zurück zum Zitat Liou AP, Paziuk M, Luevano Jr J-M, et al. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013;5:1–11. This study uses a mouse model of RYGB and transfers microbiota from mice post-RYGB, sham surgery, or sham surgery with caloric restriction into germ-free mice. Liou AP, Paziuk M, Luevano Jr J-M, et al. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013;5:1–11. This study uses a mouse model of RYGB and transfers microbiota from mice post-RYGB, sham surgery, or sham surgery with caloric restriction into germ-free mice.
160.
Zurück zum Zitat Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341:1241214.PubMed Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341:1241214.PubMed
161.••
Zurück zum Zitat Vrieze A, van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterolology. 2012;143:913–6. To our knowledge, this is the only study in humans investigating the impact of transfer of intestinal microbiota on insulin sensitivity. Vrieze A, van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterolology. 2012;143:913–6. To our knowledge, this is the only study in humans investigating the impact of transfer of intestinal microbiota on insulin sensitivity.
162.
Zurück zum Zitat Aron-Wisnewsky J, Tordjman J, Poitou C, et al. Human adipose tissue macrophages: M1 and M2 cell surface markers in subcutaneous and omental depots and after weight loss. J Clin Endocrinol Metab. 2009;94:4619–23.PubMed Aron-Wisnewsky J, Tordjman J, Poitou C, et al. Human adipose tissue macrophages: M1 and M2 cell surface markers in subcutaneous and omental depots and after weight loss. J Clin Endocrinol Metab. 2009;94:4619–23.PubMed
163.
Zurück zum Zitat Clement K. Bariatric surgery, adipose tissue and gut microbiota. Int J Obes. 2011;35:S7–15. Clement K. Bariatric surgery, adipose tissue and gut microbiota. Int J Obes. 2011;35:S7–15.
164.
Zurück zum Zitat Barres R, Kirchner H, Rasmussen M, et al. Weight loss after gastric bypass surgery in human obesity remodels promoter methylation. Cell Rep. 2013;3:1020–7.PubMed Barres R, Kirchner H, Rasmussen M, et al. Weight loss after gastric bypass surgery in human obesity remodels promoter methylation. Cell Rep. 2013;3:1020–7.PubMed
165.
Zurück zum Zitat Kirchner H, Nylen C, Laber S, et al. Altered promoter methylation of PDK4, IL1 B, IL6, and TNF after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2014;10:671–8.PubMed Kirchner H, Nylen C, Laber S, et al. Altered promoter methylation of PDK4, IL1 B, IL6, and TNF after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2014;10:671–8.PubMed
166.
Zurück zum Zitat Heneghan HM, Miller N, Kerin MJ. Role of microRNAs in obesity and the metabolic syndrome. Obes Rev. 2010;11:354–61.PubMed Heneghan HM, Miller N, Kerin MJ. Role of microRNAs in obesity and the metabolic syndrome. Obes Rev. 2010;11:354–61.PubMed
168.
Zurück zum Zitat Ortega FJ, Mercader JM, Catalán V. Targeting the circulating microRNA signature of obesity. Endocrinol Metab. 2013;59:781–92. Ortega FJ, Mercader JM, Catalán V. Targeting the circulating microRNA signature of obesity. Endocrinol Metab. 2013;59:781–92.
169.
Zurück zum Zitat Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg. 2013;23:93–102.PubMed Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg. 2013;23:93–102.PubMed
170.
Zurück zum Zitat Wang GF, Yan YX, Xu N, et al. Predictive factors of type 2 diabetes mellitus remission following bariatric surgery: a meta-analysis. Obes Surg. 2015;25:199–208.PubMedCentralPubMed Wang GF, Yan YX, Xu N, et al. Predictive factors of type 2 diabetes mellitus remission following bariatric surgery: a meta-analysis. Obes Surg. 2015;25:199–208.PubMedCentralPubMed
Metadaten
Titel
Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action
verfasst von
J. Grams
W. Timothy Garvey
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Current Obesity Reports / Ausgabe 2/2015
Elektronische ISSN: 2162-4968
DOI
https://doi.org/10.1007/s13679-015-0155-x

Weitere Artikel der Ausgabe 2/2015

Current Obesity Reports 2/2015 Zur Ausgabe

Obesity Treatment (CM Apovian, Section Editor)

Gut Microbiome and Obesity: A Plausible Explanation for Obesity

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.